BRPI0812816B8 - compostos derivados de sulfonil-quinolina, ligantes com preferência para subtipo de receptor mglur1 e mglur5, processos para a preparação dos referidos compostos, formulação farmacêutica compreendedo os referidos compostos e uso dos mesmos - Google Patents
compostos derivados de sulfonil-quinolina, ligantes com preferência para subtipo de receptor mglur1 e mglur5, processos para a preparação dos referidos compostos, formulação farmacêutica compreendedo os referidos compostos e uso dos mesmosInfo
- Publication number
- BRPI0812816B8 BRPI0812816B8 BRPI0812816A BRPI0812816A BRPI0812816B8 BR PI0812816 B8 BRPI0812816 B8 BR PI0812816B8 BR PI0812816 A BRPI0812816 A BR PI0812816A BR PI0812816 A BRPI0812816 A BR PI0812816A BR PI0812816 B8 BRPI0812816 B8 BR PI0812816B8
- Authority
- BR
- Brazil
- Prior art keywords
- compounds
- subtype
- preference
- processes
- preparation
- Prior art date
Links
- 150000001875 compounds Chemical class 0.000 title abstract 4
- FZZUESLMIHSSGS-UHFFFAOYSA-N 2-sulfonyl-1h-quinoline Chemical compound C1=CC=C2NC(=S(=O)=O)C=CC2=C1 FZZUESLMIHSSGS-UHFFFAOYSA-N 0.000 title abstract 2
- 239000003446 ligand Substances 0.000 title abstract 2
- 238000000034 method Methods 0.000 title abstract 2
- 239000008194 pharmaceutical composition Substances 0.000 title abstract 2
- 125000001072 heteroaryl group Chemical group 0.000 abstract 2
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 abstract 2
- 125000003545 alkoxy group Chemical group 0.000 abstract 1
- 125000003282 alkyl amino group Chemical group 0.000 abstract 1
- 125000000217 alkyl group Chemical group 0.000 abstract 1
- 125000004202 aminomethyl group Chemical group [H]N([H])C([H])([H])* 0.000 abstract 1
- 125000004093 cyano group Chemical group *C#N 0.000 abstract 1
- 125000004663 dialkyl amino group Chemical group 0.000 abstract 1
- 229910052736 halogen Inorganic materials 0.000 abstract 1
- 150000002367 halogens Chemical class 0.000 abstract 1
- 150000004677 hydrates Chemical class 0.000 abstract 1
- 229910052739 hydrogen Inorganic materials 0.000 abstract 1
- 239000001257 hydrogen Substances 0.000 abstract 1
- 125000004435 hydrogen atom Chemical class [H]* 0.000 abstract 1
- 125000002887 hydroxy group Chemical group [H]O* 0.000 abstract 1
- 239000000543 intermediate Substances 0.000 abstract 1
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
- 239000012453 solvate Substances 0.000 abstract 1
- 125000001424 substituent group Chemical group 0.000 abstract 1
- 238000002560 therapeutic procedure Methods 0.000 abstract 1
- 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
- C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
- C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D215/36—Sulfur atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/4709—Non-condensed quinolines and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/06—Antigout agents, e.g. antihyperuricemic or uricosuric agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/06—Antimigraine agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/06—Antiglaucoma agents or miotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/16—Otologicals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
- C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Pain & Pain Management (AREA)
- Psychiatry (AREA)
- Ophthalmology & Optometry (AREA)
- Rheumatology (AREA)
- Physical Education & Sports Medicine (AREA)
- Epidemiology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Urology & Nephrology (AREA)
- Psychology (AREA)
- Cardiology (AREA)
- Immunology (AREA)
- Hematology (AREA)
- Heart & Thoracic Surgery (AREA)
- Hospice & Palliative Care (AREA)
- Addiction (AREA)
- Child & Adolescent Psychology (AREA)
- Vascular Medicine (AREA)
- Diabetes (AREA)
- Obesity (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Quinoline Compounds (AREA)
Abstract
derivados de sulfonil-quinolina. novos ligantes com preferência para subtipo de receptor mg1ur1 e mg1ur5 de fórmula (i) e/ou sais e/ou hidratos e/ou solvatos desses, os processos e intermediários para sua preparação, composições farmacêuticas que contêm esses compostos e seu uso na terapia e/ou prevenção de uma condição que requer modulação de receptores mg1ur1 e mg1ur5, a formula (i) sendo em que ar1 representa um grupo de fenil ou heteroaril opcionalmente substituido; ar2 representa um grupo fenil substituído ou grupo heteroaril opcionalmente substituído; r1, r2, r3 e r4 representam independentemente um substituinte selecionado de hidrogênio, halogênio, ciano, alquil, alcoxi, hidroxi, trifluormetil, amino, alquilamino, dialquilamino, aminometil, alquilaminometil, dialquilaminometil.
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| HUP0700417 | 2007-06-18 | ||
| HU0700417A HU0700417D0 (en) | 2007-06-18 | 2007-06-18 | Sulfonyl-quinoline derivatives |
| HUP0800376 | 2008-06-12 | ||
| HU0800376A HUP0800376A2 (en) | 2008-06-12 | 2008-06-12 | Sulfonyl-quinoline derivatives |
| PCT/HU2008/000068 WO2008155588A1 (en) | 2007-06-18 | 2008-06-17 | Sulfonyl-quinoline derivatives |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| BRPI0812816A2 BRPI0812816A2 (pt) | 2014-12-23 |
| BRPI0812816B1 BRPI0812816B1 (pt) | 2020-09-15 |
| BRPI0812816B8 true BRPI0812816B8 (pt) | 2021-05-25 |
Family
ID=89988338
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BRPI0812816A BRPI0812816B8 (pt) | 2007-06-18 | 2008-06-17 | compostos derivados de sulfonil-quinolina, ligantes com preferência para subtipo de receptor mglur1 e mglur5, processos para a preparação dos referidos compostos, formulação farmacêutica compreendedo os referidos compostos e uso dos mesmos |
Country Status (27)
| Country | Link |
|---|---|
| EP (1) | EP2167469B1 (pt) |
| JP (1) | JP5543917B2 (pt) |
| KR (1) | KR101532101B1 (pt) |
| CN (1) | CN101730684B (pt) |
| AU (1) | AU2008264999B8 (pt) |
| BR (1) | BRPI0812816B8 (pt) |
| CA (1) | CA2690079C (pt) |
| CO (1) | CO6311082A2 (pt) |
| CU (1) | CU23822A3 (pt) |
| CY (1) | CY1113251T1 (pt) |
| DK (1) | DK2167469T3 (pt) |
| EA (1) | EA016691B1 (pt) |
| EC (1) | ECSP109884A (pt) |
| ES (1) | ES2392905T3 (pt) |
| GE (1) | GEP20125524B (pt) |
| HR (1) | HRP20120877T1 (pt) |
| IL (1) | IL202463A (pt) |
| MX (1) | MX2009013959A (pt) |
| MY (1) | MY146992A (pt) |
| NI (1) | NI200900217A (pt) |
| NZ (1) | NZ581853A (pt) |
| PL (1) | PL2167469T3 (pt) |
| PT (1) | PT2167469E (pt) |
| RS (1) | RS52495B (pt) |
| SI (1) | SI2167469T1 (pt) |
| TN (1) | TN2009000511A1 (pt) |
| WO (1) | WO2008155588A1 (pt) |
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2751761A1 (en) | 2008-10-22 | 2010-04-29 | House Ear Institute | Treatment and/or prevention of inner ear conditions by modulation of a metabotropic glutamate receptor |
| US9278960B2 (en) * | 2011-11-03 | 2016-03-08 | Merck Sharp & Dohme Corp. | Quinoline carboxamide and quinoline carbonitrile derivatives as mGluR2-negative allosteric modulators, compositions, and their use |
| RU2500672C1 (ru) * | 2012-10-25 | 2013-12-10 | Андрей Александрович Иващенко | (3-арилсульфонилхинолин-8-ил)-диалкил-амины - селективные антагонисты серотониновых 5-ht6 рецепторов, способы их получения и применения |
| AR106515A1 (es) * | 2015-10-29 | 2018-01-24 | Bayer Cropscience Ag | Sililfenoxiheterociclos trisustituidos y análogos |
| US9932310B2 (en) | 2016-02-08 | 2018-04-03 | City Of Hope | DNA2 inhibitors for cancer treatment |
| KR101893515B1 (ko) * | 2017-06-09 | 2018-08-30 | 영남대학교 산학협력단 | 구리 촉매를 이용한 4-하이드록시-3-설파닐쿠마린 유도체 또는 4-하이드록시-3-설파닐퀴놀리논 유도체의 신규 제조방법 및 이로 제조된 유도체 화합물과 이의 용도 |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ATE247652T1 (de) * | 1999-03-29 | 2003-09-15 | Neurogen Corp | 4-substituierte chinolinderivate als nk-3 und/oder gaba(a) rezeptor liganden |
| US6339093B1 (en) * | 1999-10-08 | 2002-01-15 | Hoffmann-La Roche Inc. | Isoquinoline derivatives |
| CN1703403A (zh) * | 2000-10-02 | 2005-11-30 | 詹森药业有限公司 | 趋代谢的谷氨酸盐受体拮抗剂 |
| AR039127A1 (es) * | 2002-03-27 | 2005-02-09 | Glaxo Group Ltd | Compuesto de quinolina, procedimiento para su preparacion, composicion farmaceutica que lo comprende y uso del mismo para la fabricacion de un medicamento |
| CN1845915A (zh) * | 2003-09-02 | 2006-10-11 | 默克公司 | 作为亲代谢谷氨酸受体－5的调节剂的联吡啶胺和醚类化合物 |
| JP2007516258A (ja) * | 2003-12-12 | 2007-06-21 | ワイス | 心臓血管の疾患治療に有用なキノリン誘導体 |
| GB0519765D0 (en) * | 2005-09-28 | 2005-11-09 | Glaxo Group Ltd | Novel compounds |
| US20090270371A1 (en) * | 2005-12-20 | 2009-10-29 | Gyorgy Keseru | Quinoline derivatives useful in the treatment of mglur5 receptor-mediated disorders |
-
2008
- 2008-06-17 CN CN2008800207550A patent/CN101730684B/zh active Active
- 2008-06-17 GE GEAP200811651A patent/GEP20125524B/en unknown
- 2008-06-17 SI SI200830764T patent/SI2167469T1/sl unknown
- 2008-06-17 KR KR1020097025394A patent/KR101532101B1/ko active Active
- 2008-06-17 PT PT08762671T patent/PT2167469E/pt unknown
- 2008-06-17 NZ NZ581853A patent/NZ581853A/xx unknown
- 2008-06-17 RS RS20120457A patent/RS52495B/sr unknown
- 2008-06-17 AU AU2008264999A patent/AU2008264999B8/en active Active
- 2008-06-17 CA CA2690079A patent/CA2690079C/en active Active
- 2008-06-17 BR BRPI0812816A patent/BRPI0812816B8/pt active IP Right Grant
- 2008-06-17 HR HRP20120877AT patent/HRP20120877T1/hr unknown
- 2008-06-17 JP JP2010512781A patent/JP5543917B2/ja active Active
- 2008-06-17 ES ES08762671T patent/ES2392905T3/es active Active
- 2008-06-17 MY MYPI20095244A patent/MY146992A/en unknown
- 2008-06-17 MX MX2009013959A patent/MX2009013959A/es active IP Right Grant
- 2008-06-17 DK DK08762671.9T patent/DK2167469T3/da active
- 2008-06-17 PL PL08762671T patent/PL2167469T3/pl unknown
- 2008-06-17 EP EP08762671A patent/EP2167469B1/en active Active
- 2008-06-17 EA EA201070025A patent/EA016691B1/ru unknown
- 2008-06-17 WO PCT/HU2008/000068 patent/WO2008155588A1/en not_active Ceased
-
2009
- 2009-12-02 IL IL202463A patent/IL202463A/en active IP Right Grant
- 2009-12-09 TN TNP2009000511A patent/TN2009000511A1/fr unknown
- 2009-12-15 NI NI200900217A patent/NI200900217A/es unknown
- 2009-12-16 CU CU20090219A patent/CU23822A3/es active IP Right Grant
-
2010
- 2010-01-15 CO CO10003762A patent/CO6311082A2/es active IP Right Grant
- 2010-01-18 EC EC2010009884A patent/ECSP109884A/es unknown
-
2012
- 2012-10-25 CY CY20121101007T patent/CY1113251T1/el unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AR078163A1 (es) | Utilizacion de aminodihidrotiazinas para el tratamiento o prevencion de la diabetes | |
| CR11579A (es) | Derivados de oxadiazol activos sobre fosfato de esfingosina-1 | |
| CR20110484A (es) | Nuevos derivados de benzotiazepinas su procedimiento de preparacion y composiciones farmaceuticas que los contienen | |
| BR0309397A (pt) | Derivados de n-[fenil(piperidin-2-il)metil]benzamida, sua preparação e sua aplicação em terapia | |
| CO6251248A2 (es) | Compuestos de tiazolopiridina como moduladores de sirtuina | |
| AR054799A1 (es) | Derivados de oxindol | |
| PE20181304A1 (es) | Derivados de indol n-sustituidos como moduladores de los receptores de pge2 | |
| ES2662444T3 (es) | Derivado de piridina | |
| AR021354A1 (es) | Procedimiento para la preparacion de un compuesto derivado de quinolina y un procedimiento para preparar una composicion farmaceutica | |
| BRPI0508632A (pt) | derivados de n1 ((pirazol-1-ilmetil)-2-metilfenil)-ftalamida e compostos inseticidas relacionados | |
| ECSP109884A (es) | Derivados de sulfonil-quinolina | |
| AR060812A1 (es) | Moduladores de receptores metabotropicos de glutamato mglur5, composiciones farmaceuticas que los contienen y usos en procesos patofisiologicos y trastornos que afectan el scn | |
| AR060813A1 (es) | Moduladores de mglur5 iii | |
| ES2721280T3 (es) | Nuevos inhibidores de la FYN quinasa | |
| AR053895A1 (es) | Aminopirimidinas como moduladores de quinasas | |
| CR11578A (es) | Derivados de oxadiazol activos e 1-fosfato de esfingosina | |
| PE20141527A1 (es) | Derivados de 2-amino-3-(imidazol-2-il)-piridin-4-ona, preparacion de los mismos y su uso terapeutico de los mismos | |
| BR112023004550A2 (pt) | Compostos tricíclicos substituídos | |
| BRPI0513900A (pt) | novos derivados de amida de ácido carboxìlico heterocìclicos | |
| BRPI0516841A (pt) | derivados bis-azaindóis, o respectivo preparado e a respectiva utilização farmacêutica como inibidores de quinases | |
| PE20250849A1 (es) | Derivados novedosos de indol sulfonamida 7 sustituidos | |
| BRPI0510078A (pt) | composto, composição farmacêutica, uso de um composto, e, métodos de tratamento de uma condição, distúrbios ou doença tratável com androgênios, de tratamento de uma condição, distúrbio ou doença relacionada com receptor de androgênio e de contracepção masculina | |
| AR069028A1 (es) | Derivados de 1,2,4-triazol pirrolidina fusionados como moduladores de mglur5 | |
| BRPI0510397A (pt) | compostos, composições farmacêuticas contendo os mesmos, e métodos de uso dos mesmos | |
| UY29739A1 (es) | Derivados de amidas o sales farmacéuticamente aceptables de los mismos, procesos de preparaciones farmacéuticas conteniéndolos y aplicaciones |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| B07D | Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette] | ||
| B06F | Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette] | ||
| B07E | Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette] |
Free format text: NOTIFICACAO DE ANUENCIA RELACIONADA COM O ART 229 DA LPI |
|
| B06T | Formal requirements before examination [chapter 6.20 patent gazette] | ||
| B06A | Patent application procedure suspended [chapter 6.1 patent gazette] | ||
| B06A | Patent application procedure suspended [chapter 6.1 patent gazette] | ||
| B09A | Decision: intention to grant [chapter 9.1 patent gazette] | ||
| B16A | Patent or certificate of addition of invention granted [chapter 16.1 patent gazette] |
Free format text: PRAZO DE VALIDADE: 10 (DEZ) ANOS CONTADOS A PARTIR DE 15/09/2020, OBSERVADAS AS CONDICOES LEGAIS. |
|
| B16C | Correction of notification of the grant [chapter 16.3 patent gazette] |
Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 17/06/2008 OBSERVADAS AS CONDICOES LEGAIS. PATENTE CONCEDIDA CONFORME ADI 5.529/DF |